Related Experiment Videos
Immunotherapeutic strategies for EBV-associated malignancies
R Khanna1, J Tellam, J Duraiswamy
1Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Bancroft Centre, 300 Herston Road, Herston (Qld) 4006, Brisbane, Australia. rajivK@qimr.edu.au
Trends in Molecular Medicine
|May 30, 2001
Summary
Cytotoxic T lymphocytes (CTLs) show promise in treating Epstein-Barr virus (EBV)-associated cancers. Novel therapies targeting viral antigens are being developed, but disease latency presents challenges for long-term success.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Cytotoxic T lymphocytes (CTLs) play a crucial role in controlling Epstein-Barr virus (EBV) infections.
- EBV-associated malignancies present unique challenges due to varying viral gene expression and latency phenotypes.
- Novel therapeutic strategies are emerging to target viral antigens in these cancers.
Purpose of the Study:
- To review advances in understanding CTLs and EBV-associated malignancies.
- To discuss the development of novel immunotherapeutic strategies targeting viral antigens.
- To evaluate the potential and limitations of these strategies in clinical settings.
Main Methods:
- Review of current research on CTLs and EBV.
- Analysis of therapeutic strategies targeting viral antigens.
- Evaluation of preclinical study results.
Main Results:
- Adoptive transfer of virus-specific CTLs is effective against post-transplant lymphoproliferative disease (PTLD).
- Limited viral gene expression in certain EBV malignancies (e.g., Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma) restricts immunotherapeutic efficacy.
- Preclinical studies targeting viral antigens show encouraging results.
Conclusions:
- CTL-based immunotherapies offer a promising platform for treating EBV-associated malignancies.
- Overcoming challenges related to viral latency is critical for enhancing treatment efficacy.
- Further preclinical development is essential for translating these strategies to patient treatment.